ETNB RSI Chart
Last 7 days
-1.5%
Last 30 days
-4.3%
Last 90 days
-7.9%
Trailing 12 Months
-49.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 652.0K | 1.2M | 1.7M | 2.2M |
2021 | 0 | 0 | 0 | 148.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 11, 2024 | ra capital management, l.p. | acquired | 7,500,000 | 5.325 | 1,408,450 | - |
Apr 01, 2024 | palekar rohan | sold | -575,153 | 10.91 | -52,718 | chief executive officer |
Apr 01, 2024 | palekar rohan | acquired | 48,250 | 1.93 | 25,000 | chief executive officer |
Mar 04, 2024 | ra capital management, l.p. | bought | 20,722,500 | 15.35 | 1,350,000 | - |
Feb 26, 2024 | palekar rohan | sold | -48,172 | 10.76 | -4,477 | chief executive officer |
Feb 17, 2024 | mansbach harry h | sold (taxes) | -10,188 | 9.74 | -1,046 | chief medical officer |
Feb 17, 2024 | martins ryan | sold (taxes) | -7,577 | 9.74 | -778 | chief financial officer |
Feb 17, 2024 | le-nguyen quoc | sold (taxes) | -10,188 | 9.74 | -1,046 | see remarks |
Feb 17, 2024 | palekar rohan | sold (taxes) | -44,823 | 9.74 | -4,602 | chief executive officer |
Feb 09, 2024 | palekar rohan | sold (taxes) | -107,062 | 8.45 | -12,670 | chief executive officer |
Which funds bought or sold ETNB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | Laurion Capital Management LP | reduced | -0.17 | 1,215,900 | 31,421,800 | 0.27% |
May 15, 2024 | BVF INC/IL | unchanged | - | 1,902,260 | 47,111,200 | 1.29% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | added | 18.04 | 1,621,670 | 8,671,200 | -% |
May 15, 2024 | Parkwood LLC | reduced | -39.6 | -183,000 | 311,000 | 0.03% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -75.81 | -40,102 | 13,514 | -% |
May 15, 2024 | NOMURA HOLDINGS INC | reduced | -28.09 | -229,611 | 686,329 | -% |
May 15, 2024 | QUADRANT CAPITAL GROUP LLC | sold off | -100 | -2,279 | - | -% |
May 15, 2024 | D. E. Shaw & Co., Inc. | added | 297 | 490,038 | 645,938 | -% |
May 15, 2024 | ALGERT GLOBAL LLC | reduced | -50.06 | -251,000 | 272,000 | 0.01% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 94.53 | 6,412,230 | 12,655,000 | -% |
Unveiling 89bio Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to 89bio Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.52 | 7.43 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.1B | 2.0B | -57.61 | 9.55 | ||||
BMRN | 14.6B | 2.5B | 71.11 | 5.91 | ||||
INCY | 12.8B | 3.8B | 17.13 | 3.39 | ||||
MID-CAP | ||||||||
BBIO | 5.8B | 107.9M | -10.63 | 48.09 | ||||
APLS | 5.1B | 524.1M | -12.22 | 9.73 | ||||
AXSM | 3.7B | 251.0M | -12.4 | 14.64 | ||||
ARWR | 3.1B | 240.7M | -6.6 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.4K | 3.01 | ||||
SMALL-CAP | ||||||||
NVAX | 2.0B | 996.6M | -5.07 | 2.03 | ||||
CPRX | 1.9B | 411.3M | 29.69 | 4.7 | ||||
CRBP | 489.5M | 881.7K | -14.5 | 481.06 | ||||
INO | 330.9M | 4.9M | -2.65 | 67.99 | ||||
IBIO | 15.7M | 2.1M | -0.68 | 7.61 |
89bio Inc News
Income Statement (Quarterly) | ||||||
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Operating Expenses | -6.2% | 25,362,000 | 27,041,000 | 24,738,000 | 25,108,000 | 26,241,000 |
S&GA Expenses | 30.0% | 6,298,000 | 4,844,000 | 5,052,000 | 5,259,000 | 5,262,000 |
R&D Expenses | -14.1% | 19,064,000 | 22,197,000 | 19,686,000 | 19,849,000 | 20,979,000 |
EBITDA Margin | 25.6% | -46.22 | -62.12 | -90.51 | -153 | -604 |
Interest Expenses | 1.9% | 545,000 | 535,000 | 434,000 | 408,000 | - |
Income Taxes | 700.0% | 16,000 | 2,000 | - | 1,000 | - |
Earnings Before Taxes | 8.3% | -24,586,000 | -26,803,000 | -25,054,000 | -25,564,000 | -26,435,000 |
EBT Margin | 24.7% | -47.14 | -62.56 | -91.16 | -154 | -609 |
Net Income | 8.2% | -24,602,000 | -26,805,000 | -25,054,000 | -25,565,000 | -26,288,000 |
Net Income Margin | 24.5% | -47.15 | -62.48 | -91.03 | -154 | -608 |
Free Cashflow | -82.9% | -27,098,000 | -14,815,000 | -14,834,000 | -24,350,000 | -28,267,000 |
Balance Sheet | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
Assets | -3.2% | 577 | 596 | 460 | 493 | 494 | 197 | 201 | 148 | 136 | 162 | 168 | 182 | 199 | 211 | 223 | 77.00 | 88.00 | 96.00 | 18.00 | 11.00 |
Current Assets | -3.2% | 575 | 594 | 460 | 492 | 494 | 196 | 200 | 147 | 135 | 162 | 167 | 181 | 198 | 210 | 223 | 75.00 | 87.00 | 95.00 | 17.00 | 11.00 |
Cash Equivalents | -31.2% | 218 | 316 | 252 | 245 | 351 | 55.00 | 72.00 | 61.00 | 55.00 | 52.00 | 40.00 | 36.00 | 68.00 | 98.00 | 142 | 68.00 | 86.00 | 93.00 | 16.00 | 11.00 |
Net PPE | -19.6% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 11.4% | 67.00 | 60.00 | 50.00 | 51.00 | 48.00 | 45.00 | 48.00 | 67.00 | 33.00 | 36.00 | 21.00 | 9.00 | - | 8.00 | - | - | - | - | - | - |
Current Liabilities | 29.1% | 38.00 | 30.00 | 25.00 | 26.00 | 24.00 | 25.00 | 34.00 | 27.00 | 18.00 | 20.00 | 20.00 | 8.00 | 8.00 | 8.00 | 9.00 | 7.00 | 8.00 | 6.00 | 23.00 | 4.00 |
Long Term Debt | -7.0% | 23.00 | 25.00 | 25.00 | 24.00 | 24.00 | 20.00 | 13.00 | 12.00 | 14.00 | 17.00 | 1.00 | 1.00 | - | - | - | - | - | - | - | - |
LT Debt, Current | - | 2.00 | - | - | - | - | - | 7.00 | 8.00 | 5.00 | 3.00 | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | -100.0% | - | 25.00 | 25.00 | 24.00 | 24.00 | 20.00 | 13.00 | 12.00 | 14.00 | 17.00 | 1.00 | 1.00 | - | - | - | - | - | - | - | - |
Shareholder's Equity | -4.8% | 511 | 536 | 410 | 442 | 446 | 152 | 153 | 80.00 | 103 | 126 | 147 | 173 | 190 | 203 | 214 | 70.00 | 80.00 | 90.00 | - | - |
Retained Earnings | -11.3% | -509 | -457 | -417 | -382 | -344 | -315 | -290 | -263 | -238 | -213 | -186 | -158 | -137 | -123 | -110 | -95.91 | -84.14 | -73.60 | -54.31 | -16.18 |
Additional Paid-In Capital | -100.0% | - | 993 | 828 | 825 | 790 | 467 | 444 | 344 | 342 | 339 | 334 | 331 | 328 | 326 | 325 | 166 | 164 | 164 | 0.00 | 0.00 |
Shares Outstanding | 2.1% | 95.00 | 93.00 | 76.00 | 74.00 | 53.00 | 51.00 | 29.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 1,176 | - | - | - | 30.00 | - | - | - | 166 | - | - | - | 72,707,052 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -15.8% | -39,720 | -34,293 | -30,361 | -34,447 | -30,085 | -27,096 | -14,815 | -14,835 | -24,344 | -28,240 | -13,450 | -20,109 | -14,982 | -14,028 | -12,940 | -11,524 | -7,752 | -11,132 | -6,197 | -3,964 | -4,167 |
Share Based Compensation | 23.8% | 4,998 | 4,037 | 4,381 | 4,137 | 3,551 | 2,758 | 2,500 | 2,586 | 2,512 | 2,154 | 2,314 | 2,417 | 1,793 | 1,250 | 1,154 | 910 | 493 | 166 | 112 | 76.00 | 35.00 |
Cashflow From Investing | -25.5% | -79,898 | -63,643 | 38,326 | -101,808 | 4,106 | -11,061 | -42,058 | -7,596 | 26,772 | 19,086 | 17,359 | -13,876 | -15,410 | -29,028 | -71,999 | -5,744 | -61.00 | -111 | -8.00 | -18.00 | -2.00 |
Cashflow From Financing | -87.0% | 21,030 | 162,171 | -1,480 | 30,766 | 321,654 | 21,011 | 68,631 | 28,160 | 29.00 | 21,891 | 72.00 | 1,692 | 216 | -312 | 158,292 | -65.00 | 9.00 | 88,377 | 488 | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 47,428 | $ 22,306 |
General and administrative | 9,849 | 6,218 |
Total operating expenses | 57,277 | 28,524 |
Loss from operations | (57,277) | (28,524) |
Interest expense | (863) | (2,075) |
Interest income and other, net | 6,556 | 1,763 |
Net loss before income tax | (51,584) | (28,836) |
Income tax expense | (97) | 0 |
Net loss | (51,681) | (28,836) |
Other comprehensive (loss) income: | ||
Unrealized (loss) gain on marketable securities | (714) | 114 |
Foreign currency translation adjustments | 5 | (4) |
Total other comprehensive (loss) income | (709) | 110 |
Comprehensive loss | $ (52,390) | $ (28,726) |
Net loss per share, basic | $ (0.54) | $ (0.54) |
Net loss per share, diluted | $ (0.54) | $ (0.54) |
Weighted-average shares used to compute net loss per share, basic | 95,846,740 | 53,171,370 |
Weighted-average shares used to compute net loss per share, diluted | 95,846,740 | 53,171,370 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 217,573 | $ 316,161 |
Marketable securities | 344,715 | 262,709 |
Prepaid and other current assets | 12,494 | 14,664 |
Total current assets | 574,782 | 593,534 |
Operating lease right-of-use assets | 2,118 | 2,293 |
Property and equipment, net | 37 | 46 |
Other assets | 385 | 396 |
Total assets | 577,322 | 596,269 |
Current liabilities: | ||
Accounts payable | 15,352 | 8,585 |
Accrued expenses | 20,295 | 20,530 |
Operating lease liabilities, current | 702 | 496 |
Term loan, current | 1,892 | 0 |
Total current liabilities | 38,241 | 29,611 |
Operating lease liability, non-current | 1,640 | 1,817 |
Term loan, noncurrent, net | 23,065 | 24,795 |
Other noncurrent liabilities | 3,837 | 3,740 |
Total liabilities | 66,783 | 59,963 |
Commitments and contingencies (Note 5) | ||
Stockholders’ equity: | ||
Common stock, $0.001 par value: 200,000,000 shares authorized; 95,199,724 and 93,269,377 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 95 | 93 |
Additional paid-in capital | 1,020,076 | 993,455 |
Accumulated other comprehensive (loss) income | (519) | 190 |
Accumulated deficit | (509,113) | (457,432) |
Total stockholders’ equity | 510,539 | 536,306 |
Total liabilities and stockholders’ equity | $ 577,322 | $ 596,269 |
 | Mr. Rohan Palekar |
---|---|
 | 89bio.com |
 | Biotechnology |
 | 45 |